Akèy › Kansè poumon › Kalifòni › Orange
Etid klinik pou Kansè poumon nan Orange, CA
14 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Orange (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- University of California, Irvine Health, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- UC IRVINE Health, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Ap rekrite
- Primary Care & Internal Medicine Services, Orange
- UCI Chao Family Comprehensive Cancer Center, Orange
- UCI Health SeniorHealth Center -Pavillion 4, Orange
- ak 1 plis
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Providence St. Joseph Hospital, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
Ap rekriteEtid obsèvasyon
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Ap rekriteFaz 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Ap rekriteFaz 2
- University of California, Irvine Medical Center, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Ap rekriteFaz 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Orange
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
Ap rekrite
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Orange
- Kansè Poumon ki pa ti selil25 etid
- Kansè Metastatik20 etid
- Kansè kolorektal16 etid
- Kansè ovè16 etid
- Kansè pankreyas15 etid
- Kansè nan tete14 etid
- Kansè pwostat14 etid
- Kansè fwa (Kasinòm epatoselilè)14 etid
- Melanom14 etid
- Leksemi mieloïd egi13 etid
- Kansè (tout kalite)13 etid
- Kansè lestomak13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.